10058-F4: Benchmark Small-Molecule c-Myc-Max Dimerization Inhibitor

Executive Summary: 10058-F4 is a cell-permeable small-molecule inhibitor that specifically disrupts c-Myc-Max heterodimerization, essential for c-Myc transcriptional activity (APExBIO). This compound suppresses c-Myc-driven transcription by preventing DNA binding, leading to cell cycle arrest and mitochondrial apoptosis in several cancer cell lines (Stern et al., 2024). Efficacy has been validated in acute myeloid leukemia (AML) cell lines (HL-60, U937, NB-4) and in vivo in prostate cancer xenograft models. 10058-F4 is chemically identified as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one, with defined solubility parameters and stability guidelines. This article provides a structured, verifiable overview for researchers integrating 10058-F4 into apoptosis and c-Myc pathway studies.

Biological Rationale

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor that regulates genes controlling cell proliferation, metabolism, and survival. Its oncogenic potential depends on heterodimerization with Max, forming a complex that binds E-box sequences in DNA to activate transcription (Stern et al., 2024). Overexpression or dysregulation of c-Myc is observed in multiple malignancies, including AML and prostate cancer. Targeting c-Myc-Max dimerization is a strategy to inhibit c-Myc-driven oncogenic transcriptional programs. 10058-F4 was developed to exploit this therapeutic axis by directly blocking the c-Myc/Max interaction (see related article – this article provides an updated overview with new in vivo parameters).

Mechanism of Action of 10058-F4

10058-F4 binds selectively to the c-Myc bHLH-LZ domain, impeding its association with Max. This disruption prevents the formation of the active c-Myc/Max heterodimer. The compound thereby inhibits c-Myc binding to E-box DNA elements, blocking transcriptional activation of c-Myc target genes (APExBIO). Downstream, this leads to:

• Decreased c-Myc mRNA and protein expression.
• Suppression of c-Myc-dependent transcriptional programs.
• Induction of G1 cell cycle arrest.
• Activation of mitochondrial apoptosis via Bcl-2 family modulation and cytochrome C release.

This targeted mechanism differentiates 10058-F4 from non-specific transcription inhibitors. The compound is not active against Max homodimers or other bHLH-LZ factors at comparable concentrations (see also: Q&A-driven scenarios, for protocol-specific troubleshooting).

Evidence & Benchmarks

• 10058-F4 induces apoptosis in AML cell lines (HL-60, U937, NB-4) in a dose-dependent manner, with significant effects observed at 100 μM after 72 hours in RPMI 1640 medium (Stern et al., 2024, https://doi.org/10.1101/2024.09.23.614488).
• In SCID mice bearing human prostate cancer xenografts (DU145, PC-3), intravenous 10058-F4 administration resulted in tumor growth inhibition at 15 mg/kg, with variable efficacy depending on tumor model and dosing regimen (APExBIO).
• 10058-F4 reduces c-Myc protein levels by >40% (relative to control) after 48 hours in NB-4 leukemia cells, with parallel decreases in c-Myc mRNA (Stern et al., 2024, DOI).
• Apoptosis induction correlates with increased mitochondrial cytochrome C release and decreased Bcl-2 expression, supporting activation of the intrinsic apoptotic pathway (see: advanced insights – this article benchmarks new solubility and storage data).
• 10058-F4 is soluble at ≥24.9 mg/mL in DMSO and ≥2.64 mg/mL in ethanol, but is insoluble in water; solutions should be used promptly and not stored long-term (APExBIO).

Applications, Limits & Misconceptions

10058-F4 is primarily employed in research investigating c-Myc-dependent oncogenic pathways, apoptosis assays, and transcription factor inhibition in cancer biology. It is a diagnostic tool for verifying c-Myc dependency in cellular models and can be used in combination with other pathway inhibitors. Its cell permeability enables both in vitro and in vivo applications.

For further scenario-based application advice, see this comparative guidance – this article adds new evidence on mitochondrial pathway readouts.

Common Pitfalls or Misconceptions

• 10058-F4 is not effective in non-c-Myc-dependent cell lines; lack of apoptosis may indicate pathway independence.
• The compound does not inhibit Max homodimerization or other bHLH-LZ transcription factors at recommended concentrations.
• Water is not a suitable solvent; use DMSO or ethanol for stock solutions.
• Solutions are unstable for long-term storage; always prepare fresh before use.
• In vivo efficacy is model- and dose-dependent; optimization is required for new xenograft systems.

Workflow Integration & Parameters

The recommended workflow for apoptosis or c-Myc pathway studies with 10058-F4:

1. Prepare fresh stock in DMSO (≥24.9 mg/mL) or ethanol (≥2.64 mg/mL); dilute into culture medium immediately before use (APExBIO product page).
2. Apply to cells at 10–100 μM, depending on cell line sensitivity; optimal for AML lines at 100 μM for 72 h at 37°C, 5% CO₂ (Stern et al., 2024, DOI).
3. For in vivo models, start with 15 mg/kg intravenous dosing and titrate as required; monitor tumor volume and animal health.
4. Assess c-Myc protein/mRNA levels, cell cycle distribution, and apoptosis markers (e.g., Annexin V/PI, cytochrome C release).
5. Store unused solid at -20°C; avoid repeated freeze-thaw cycles.

For protocol troubleshooting, refer to this Q&A resource – this article provides fresh benchmarks and clinical translation context.

Conclusion & Outlook

10058-F4 remains a reference standard for small-molecule c-Myc-Max dimerization inhibition in apoptosis and cancer biology research. Its validated mechanism, defined solubility, and action in AML and prostate cancer models are backed by quantitative, peer-reviewed data. Researchers should adhere to recommended handling and dosing protocols for reproducible results. Ongoing studies are expanding its use in telomerase and DNA repair pathway intersect research (Stern et al., 2024). For detailed product parameters and ordering, see the APExBIO 10058-F4 product page.